Brain Cancer - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 183

Brain Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Brain Cancer - Pipeline Review, H1 2012', provides an overview of the Brain Cancer therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. 'Brain Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Brain Cancer.
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Brain Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Brain Cancer Therapeutic Products under Development, Key Players in Brain Cancer Therapeutics, Brain Cancer Pipeline Overview, Brain Cancer Pipeline, Brain Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Brain Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Brain Cancer
Brain Cancer Therapeutics under Development by Companies
Brain Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Brain Cancer Therapeutics – Products under Development by Companies
Brain Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Brain Cancer Therapeutics Development
Abbott Laboratories
United Therapeutics Corporation
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Alkermes, Inc.
YM BioSciences Inc.
Aposense Ltd.
Advocate Health Care
Novartis AG
Dong-A Pharmaceutical Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Celgene Corporation
Geron Corporation
Advaxis, Inc.
4SC AG
GW Pharmaceuticals plc
Bionomics Limited
Peregrine Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
TopoTarget A/S
Mundipharma International Limited
Protox Therapeutics Inc.
e-Therapeutics plc
Morphotek, Inc.
Spectrum Pharmaceuticals, Inc.
Ambit Biosciences Corporation
Philogen S.p.A.
BioNumerik Pharmaceuticals, Inc.
Oncolin Therapeutics, Inc.
Pervasis Therapeutics, Inc.
Nobelpharma Co., Ltd.
Stemline Therapeutics, Inc.
BiPar Sciences, Inc.
Globeimmune, Inc.
Kinex Pharmaceuticals, LLC
to-BBB technologies BV
Archer Biosciences, Inc
Advanced Cancer Therapeutics
VectorLogics, Inc.
Brain Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Hycamtin + Whole Brain Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herceptin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TransMID - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
memantine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide phosphate + Ifosfamide + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin+ Etoposide phosphate + Ifosfamide + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Thiosulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation Therapy + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cyclophosphamide + Etoposide + Irinotecan + Temozolomide + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
porfimer sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide + Ifosfamide + Lomustine + Methotrexate + Prednisone + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Carmustine + Lomustine + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Vincristine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Lomustine + Vincristine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Vincristine + Etoposide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Etoposide + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cyclophosphamide + Etoposide + Vincristine + Doxorubicin + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Lomustine + Vincristine Sulfate + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brain Cancer Therapeutics – Discontinued Products
Brain Cancer Therapeutics - Dormant Products
Brain Cancer – Product Development Milestones
Featured News & Press Releases
Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer
Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC
Nov 01, 2011: Telik Announces Ezatiostat Preclinical Presentation At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors
Sep 08, 2011: Novartis Receives EU Approval For Votubia
Sep 06, 2011: DelMar Pharma Receives FDA IND Approval To Begin Clinical Trials With New Brain Cancer Treatment
Aug 04, 2011: Northwest Biotherapeutics Announces Further Expansion Of Clincal Sites In Ongoing Brain Cancer Trial
Jun 27, 2011: to-BBB Starts Clinical Trial In Patients With Brain Metastases
Jun 02, 2011: Stemline Therapeutics Announces Presentation Of Positive Phase I/II Trial Results With New Brain Cancer Vaccine At ASCO 2011 Annual Meeting
May 18, 2011: Northwest Biotherapeutics And Fraunhofer Partner For Clinical Trials And Compassionate Use Cases In Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Brain Cancer, H1 2012
Products under Development for Brain Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
Abbott Laboratories, H1 2012
United Therapeutics Corporation, H1 2012
Eli Lilly and Company, H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Alkermes, Inc., H1 2012
YM BioSciences Inc., H1 2012
Aposense Ltd., H1 2012
Advocate Health Care, H1 2012
Novartis AG, H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Nippon Shinyaku Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Celgene Corporation, H1 2012
Geron Corporation, H1 2012
Advaxis, Inc., H1 2012
4SC AG, H1 2012
GW Pharmaceuticals plc, H1 2012
Bionomics Limited, H1 2012
Peregrine Pharmaceuticals, Inc., H1 2012
Critical Outcome Technologies Inc., H1 2012
TopoTarget A/S, H1 2012
Mundipharma International Limited, H1 2012
Protox Therapeutics Inc., H1 2012
e-Therapeutics plc, H1 2012
Morphotek, Inc., H1 2012
Spectrum Pharmaceuticals, Inc., H1 2012
Ambit Biosciences Corporation, H1 2012
Philogen S.p.A., H1 2012
BioNumerik Pharmaceuticals, Inc., H1 2012
Oncolin Therapeutics, Inc., H1 2012
Pervasis Therapeutics, Inc., H1 2012
Nobelpharma Co., Ltd., H1 2012
Stemline Therapeutics, Inc., H1 2012
BiPar Sciences, Inc., H1 2012
Globeimmune, Inc., H1 2012
Kinex Pharmaceuticals, LLC, H1 2012
to-BBB technologies BV, H1 2012
Archer Biosciences, Inc, H1 2012
Advanced Cancer Therapeutics, H1 2012
VectorLogics, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Brain Cancer Therapeutics – Discontinued Products
Brain Cancer Therapeutics – Dormant Products
Brain Cancer Therapeutics – Dormant Products (Contd..1)
Brain Cancer Therapeutics – Dormant Products (Contd..2)
Brain Cancer Therapeutics – Dormant Products (Contd..3)
Brain Cancer Therapeutics – Dormant Products (Contd..4)
Brain Cancer Therapeutics – Dormant Products (Contd..5)
Brain Cancer Therapeutics – Dormant Products (Contd..6)

List of Figures
Number of Products under Development for Brain Cancer, H1 2012
Products under Development for Brain Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Brain Cancer - Pipeline Review, H2 2012
• Brain Tumor – Pipeline Review, H1 2013
• Anemia - Pipeline Review, H1 2012
• Lymphoma - Pipeline Review, H2 2012
• Myelodysplastic Syndrome - Pipeline Review, H1 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2012
• Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2013
• Astrocytoma - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, H2 2012